Inhibrx, Inc. (INBX)
NASDAQ: INBX · IEX Real-Time Price · USD
34.70
+0.21 (0.61%)
At close: May 17, 2024, 4:00 PM
34.54
-0.16 (-0.46%)
After-hours: May 17, 2024, 5:15 PM EDT
Inhibrx Revenue
Inhibrx had revenue of $1.78M in the twelve months ending March 31, 2024, with 39.30% growth year-over-year. In the year 2023, Inhibrx had annual revenue of $1.80M, a decrease of -17.88%.
Revenue (ttm)
$1.78M
Revenue Growth
+39.30%
P/S Ratio
1,020.71
Revenue / Employee
$10,366
Employees
172
Market Cap
1.82B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.80M | -392.00K | -17.88% |
Dec 31, 2022 | 2.19M | -5.04M | -69.69% |
Dec 31, 2021 | 7.23M | -5.66M | -43.89% |
Dec 31, 2020 | 12.89M | -323.00K | -2.44% |
Dec 31, 2019 | 13.21M | 4.62M | 53.71% |
Dec 31, 2018 | 8.60M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Addus HomeCare | 1.09B |
Veracyte | 375.47M |
Protagonist Therapeutics | 314.95M |
Ginkgo Bioworks Holdings | 208.70M |
LeMaitre Vascular | 199.89M |
Ardelyx | 159.11M |
Fusion Pharmaceuticals | 2.04M |
INBX News
- 8 days ago - Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off - PRNewsWire
- 9 days ago - INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX - Business Wire
- 10 days ago - Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger - PRNewsWire
- 2 months ago - Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results - PRNewsWire
- 4 months ago - Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi - PRNewsWire
- 4 months ago - Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline - Investopedia
- 4 months ago - INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders - Business Wire
- 4 months ago - Sanofi to Buy Rare-Disease Assets From Inhibrx - WSJ